Figure 1
From: Irinotecan plus carboplatin for patients with carcinoma of unknown primary site
Kaplan–Meier analysis to determine the time to progression (dotted line) and overall survival (solid line).
Figure 1 | British Journal of Cancer
From: Irinotecan plus carboplatin for patients with carcinoma of unknown primary site
Kaplan–Meier analysis to determine the time to progression (dotted line) and overall survival (solid line).
